Beam Therapeutics Inc. — Form 10-Q Summary
Business context and reporting period
Beam Therapeutics is an early-stage biotechnology company developing precision genetic medicines using base-editing, delivery and manufacturing technologies. The filing covers the quarter and nine months ended September 30, 2021, and was filed November 8, 2021. The company had no product sales and its programs remained primarily preclinical, although it was preparing for clinical development of BEAM-101.
Financial performance and liquidity
| Metric | Q3 2021 | Q3 2020 | 9M 2021 | 9M 2020 |
|---|---|---|---|---|
| License and collaboration revenue | $0.8 million | $0.01 million | $0.8 million | $0.02 million |
| Research and development expense | $54.6 million | $29.8 million | $290.3 million | $70.7 million |
| General and administrative expense | $15.8 million | $7.5 million | $39.5 million | $21.3 million |
| Loss from operations | $(69.6) million | $(37.3) million | $(329.0) million | $(92.0) million |
| Net loss | $(28.1) million | $(34.5) million | $(305.9) million | $(99.1) million |
| Net loss per share | $(0.42) | $(0.69) | $(4.86) | $(2.31) |
- Operating cash flow was $(68.1) million for the nine months ended September 30, 2021, compared with $(71.4) million in the prior-year period.
- Investing cash flow was $(216.6) million, primarily reflecting net purchases of marketable securities of $183.8 million and property and equipment purchases of $33.4 million.
- Financing cash flow was $734.6 million, principally from equity offerings. The company raised $252.0 million net in a January 2021 private placement and received aggregate gross proceeds of $490.5 million under its ATM program through September 30, 2021.
- Cash, cash equivalents and marketable securities totaled $933.4 million at September 30, 2021. Cash, cash equivalents and restricted cash totaled $626.9 million.
- The company reported an accumulated deficit of $703.6 million and expects continuing operating losses and negative operating cash flow.
- Total liabilities were $302.7 million, including $139.6 million of operating lease liabilities, $49.6 million of success-payment derivative liabilities, $26.96 million of Guide contingent consideration liabilities and $5.8 million of equipment financing liabilities. The filing does not identify significant conventional funded debt.
Material changes versus the prior comparable period
- Nine-month research and development expense increased by $219.6 million, largely because of a $155.0 million charge for acquired in-process research and development from the Guide acquisition, which was treated as having no alternative future use.
- Research and development staffing increased from 136 employees at September 30, 2020 to 250, while general and administrative staffing increased from 30 to 56 employees.
- General and administrative expense increased $18.2 million for the nine-month period, driven mainly by higher personnel, stock-based compensation, facilities, insurance and legal costs.
- Quarterly net loss improved by $6.3 million despite higher operating expenses, primarily because of $35.8 million of other income from the decrease in the fair value of success-payment liabilities and $10.6 million of income from the decrease in Guide contingent consideration liabilities.
- Nine-month net loss increased $206.8 million, reflecting the Guide acquisition charge and substantially higher development spending.
- Guide was acquired for $120.0 million of upfront equity consideration. Former Guide holders may receive up to an additional $100.0 million in technology milestones and $220.0 million in product milestones, payable in common stock.
- Apellis provided a $50.0 million upfront payment in July 2021. The company recognized only $0.8 million of related revenue in the quarter and reported $49.2 million of current and non-current deferred revenue at September 30, 2021.
Guidance, outlook, commentary and risks
- Management stated that cash, cash equivalents and marketable securities at September 30, 2021 were expected to fund operations for at least the next 12 months, but additional financing will be needed to support continued operations and growth.
- Management expected research and development expenses to increase as BEAM-101 clinical activities, BEAM-102 IND-enabling work, BEAM-201 development, other preclinical programs and manufacturing investments advance.
- The company expected to nominate its first in vivo liver base-editing development candidate for GSDIa, targeting the R83C mutation, by the end of 2021.
- The company anticipated that its 100,000-square-foot cGMP manufacturing facility in North Carolina would be operational in the first quarter of 2023. The lease carried an initial estimate of $81.1 million of undiscounted minimum payments, excluding certain other facility commitments.
- Key risks include the absence of human clinical data for base editing, potential off-target or permanent DNA edits, adverse reactions to LNP or viral delivery systems, clinical and regulatory failure, manufacturing delays, dependence on third parties, intellectual-property interference proceedings and the need for additional capital.
- The filing stated that COVID-19 had not significantly affected operations during the nine months ended September 30, 2021, but future effects remained uncertain.
- Subsequent to quarter-end, the company entered into a Sana Biotechnology agreement and received a $50.0 million upfront payment in October 2021 for non-exclusive Cas12b commercial rights, excluding base editing rights.
Important facts for investors to verify
- Whether the reported $933.4 million liquidity balance and projected funding runway remain adequate as clinical, manufacturing and facility costs accelerate.
- The extent to which the $155.0 million Guide acquisition charge distorts year-to-date results and the probability and dilution impact of up to $320.0 million of additional Guide milestone consideration.
- Timing and regulatory status of BEAM-101, BEAM-102 and BEAM-201 clinical or IND-enabling activities; the filing includes later November 2021 developments that are outside the September 30 reporting period.
- Progress toward the first GSDIa development candidate and the operational readiness and total cost of the North Carolina manufacturing facility.
- Future fair-value changes and settlement requirements for the $49.6 million of Harvard and Broad success-payment liabilities.
- Potential dilution from continued ATM equity sales, stock-based compensation, outstanding options and milestone payments payable in common stock.
- The status and potential effect of the disclosed CRISPR-related patent interference proceedings and other intellectual-property disputes.